Testosterone Replacement Therapy Dosing Regimen
For adult males with confirmed hypogonadism, initiate testosterone cypionate or enanthate 200 mg intramuscularly every 2 weeks, or testosterone gel 2% (23-46 mg/day) applied topically, with the goal of achieving mid-normal testosterone levels (450-600 ng/dL). 1, 2
Initial Dosing Strategy
The choice between formulations should prioritize intramuscular testosterone over transdermal preparations when cost is a consideration, as clinical effectiveness and adverse effects are similar but intramuscular formulations are considerably less expensive 3.
Intramuscular Testosterone (Preferred for Cost-Effectiveness)
- Testosterone enanthate or cypionate: 200 mg IM every 2 weeks is the most effective regimen balancing efficacy with administration frequency 4
- Alternative: 300 mg every 3 weeks also effectively suppresses LH to normal levels 4
- Avoid 400 mg every 4 weeks—this fails to adequately suppress LH and provides suboptimal testosterone levels 4
Transdermal Testosterone Gel
- Start with 23 mg/day (single pump actuation) 5
- Uptitrate to 46 mg/day after 2 weeks if 4-hour post-application testosterone is <500 ng/dL 5
- Can further adjust between 23-69 mg/day based on response 5
- Approximately 76% of patients achieve target testosterone levels with this approach 5
Target Testosterone Levels
Maintain serum testosterone in the mid-normal range: 450-600 ng/dL (15.6-20.8 nmol/L) during treatment 1, 2. This is the therapeutic sweet spot that balances efficacy with safety.
Monitoring Protocol
Initial Phase (First 3-6 Months)
Measure testosterone and hematocrit at 3-6 months after initiation 1:
For IM testosterone: Draw blood midway between injections
- If mid-interval testosterone >600 ng/dL: reduce dose or increase interval
- If mid-interval testosterone <350 ng/dL: increase dose or shorten interval 1
For transdermal gel: Measure 2-8 hours after application (after ≥1 week of use) 1
Ongoing Monitoring
- Testosterone and hematocrit at 12 months, then annually 1
- Clinical symptom assessment at 3-12 months, then every 6-12 months 1, 2
- For men >50 years: PSA and digital rectal exam at 3-12 months, then annually 1
Critical Decision Point: Reassess at 12 Months
Discontinue testosterone if there is no improvement in symptoms (particularly sexual function) after 12 months 3. This is essential—continuing ineffective therapy exposes patients to risks without benefit.
Important Caveats
Who Should NOT Receive TRT
The evidence does not support initiating testosterone to improve energy, vitality, physical function, or cognition in men with age-related low testosterone 3. These are not appropriate indications.
Obesity-Induced Hypogonadism
Weight loss is first-line treatment, not testosterone 6. Weight loss of ≥5% significantly increases testosterone and improves sexual function 6. Reserve TRT for men with permanent hypogonadism or those unable to achieve weight loss.
Safety Monitoring Red Flags
- Hematocrit elevation: Most common with long-acting IM formulations; requires dose adjustment if hematocrit rises excessively 2, 7
- PSA increase >1.4 ng/mL above baseline or PSA >4.0 ng/mL: Requires urological consultation 1
- Fertility suppression: TRT suppresses spermatogenesis; counsel patients desiring fertility 2
Formulation-Specific Considerations
Transdermal gels have favorable local skin tolerability 5 but cost significantly more than IM preparations 3. The 200 mg every 2 weeks IM regimen remains the gold standard for balancing efficacy, tolerability, and cost-effectiveness 4.